Alkem LabQ1 FY27
Alkem Lab Q1 FY27 Earnings Call Analysis
Revenue, margin, capex, fundraise and order book outlook from management commentary.
Price: ₹5,368P/E: 28.4Market Cap: ₹64.6K CrSector: Pharmaceuticals & Biotechnology
Management growth scorecard
Revenue
Category 3
Margin
Category 3
Fundraise
No
Order
N/A
Capex
Yes
1 of 4 growth signals are positive — mixed outlook.
Full analysisRevenue guidance
Category 3- →**International Business:** Sustainable double-digit growth expected, driven by smaller markets like Germany (35-40% growth), Chile, and Australia. U.S. business remains flat to high single-digit growth due to pricing pressure and currency effects.
- →**U.S. Market:** Anticipated growth in high single to mid-single digits in FY27, helped by currency benefits. No major volume expansion seen in last 12-24 months.
- →**India Business:** Branded formulations expected to grow around 12%; Trade Generics growth slower—late single digits anticipated with disciplined execution.
- →**CDMO Business:** Revenue of USD 30 million targeted by FY28; breakeven expected when such revenue is achieved.
- →**Overall:** India market expected to outperform industry by 100 basis points; chronic and acute segments showing sustained growth; continued focus on execution and disciplined growth.
Margin guidance
Category 3- →India business growth is expected around 12% for the full year, slightly better than previous guidance.
- →U.S. business expected to grow in high single digits to mid-single digits, aided by currency impacts.
- →International markets outside the U.S., especially smaller bases like Germany, Chile, and Australia, show healthy double-digit growth, though on a small base.
- →CDMO business in the U.S. aims for breakeven with revenue target around USD 25-30 million by FY28; operational expenses around INR 60 crores quarterly continue until then.
- →Gross margins guidance maintained at 66.5% to 67% despite anticipated API price increases.
- →EBITDA expected to improve 7-8% year-on-year with significant EBITDA business scale-up over 3-4 years, supported by integration and operational efficiencies.
- →Overall revenue growth guidance around 11%, with profit before tax growth nearly flat and net profit impacted by taxation changes.
3 more insights locked — sign up free to unlock
Fundraise plans
No- →There are no current or planned new fundraisings through debt or equity.
- →The company has around INR 5,700 crores in cash.
- →Management mentioned no change from the previous quarter regarding fundraising plans.
- →No specific plans for capital raising were shared during the call.
Order book
- →The exact number of pending ANDAs (Abbreviated New Drug Applications) for the Daman facility is not specified; the management mentioned they would provide this information later.
- →For the U.S. CDMO (Contract Development and Manufacturing Organization) business, the revenue breakeven is expected at an annualized USD 25-30 million run rate.
- →The CDMO business has a decent project pipeline but the sales cycle is long and lumpy, dependent on client funding and clinical trial progress.
- →The company anticipates CDMO revenues to start rising in FY27 and FY28, with the USD 30 million revenue target expected by FY28.
- →The Daman plant faced an OAI (Official Action Indicated) status but continues supplying products without interruption, with resolution expected in 6-12 months.
- →45% of U.S. revenues come from the Daman facility.
Capex plans
Yes- →The company currently has reasonable capacity at its CDMO facility in the U.S., with some specialized technology; however, it is relatively small.
- →Future capex will be required at the CDMO facility to ramp up production and achieve economies of scale, but this is not expected to happen in the current fiscal year.
- →No plans for acquisitions in the orthopedics or MedTech segment at present; focus is on ramping up existing operations.
- →The Daman plant has received an OAI status, and corrective actions are underway; no expected impact on capex specifics mentioned.
- →Overall, capex related to CDMO expansion is planned but timed based on business growth and scale requirements.
How does Alkem Lab rank vs peers in Pharmaceuticals & Biotechnology?
Pro feature1Alkem Lab
Rev 3Mar 3
See full Pharmaceuticals & Biotechnology sector rankings
How does Alkem Lab rank in Pharmaceuticals & Biotechnology?
Compare Alkem Lab against every Pharmaceuticals & Biotechnology company (Q1 FY27) on revenue, margins and earnings-call signals.